Everest Organics board meet Aug 14, 2026 for Q1 results

Stock in focus ahead of board meeting

Everest Organics Ltd is scheduled to hold a Board meeting on August 14, 2026. The company said the key items on the agenda include approval of unaudited financial results for the quarter ended June 30, 2026, and fixing details for its upcoming 33rd Annual General Meeting (AGM). With the results and AGM schedule expected to be finalised, the stock is likely to stay on investor watchlists in the near term.

EVERESTO was quoted at ₹305 as of August 13, 2026, based on the data provided. The same dataset also shows a BSE reference price of ₹261.75 (up 0.71% or ₹1.85) at 4:00 PM on May 8. These datapoints indicate the market has seen meaningful price movement over recent months, even as the company’s recent profitability trend has been uneven.

What the August 14 board agenda covers

The board meeting is expected to focus on two clear deliverables. First is the approval of the unaudited financial results for the quarter ended June 30, 2026. Second is finalising the date and other details for the company’s 33rd AGM.

Quarterly results matter because they provide the most current snapshot of sales, costs, operating performance, and profit after tax. AGM-related resolutions and timelines are also closely tracked by shareholders, particularly when they include decisions tied to governance, appointments, or shareholder approvals. The company has not disclosed any additional agenda items in the text provided beyond results approval and the AGM.

Company profile and key fundamentals in the dataset

Everest Organics is classified under the Pharmaceuticals industry and the Health Care or Life Sciences sector. The fiscal year-end is listed as 03/2027. The dataset lists revenue at ₹1.96B, which is ₹196.00 crore after unit normalisation, and net income at ₹55.47M, which is ₹5.55 crore.

Sales growth for 2026 is stated at 23.00%. The same dataset reports Return on Equity (ROE) at -2.2482% and Return on Capital Employed (ROCE) at 1.7587%. Quarterly earnings growth year-on-year is shown as -9.62, and the narrative also states net profit fell 9.62% versus the same period last year.

Recent quarterly performance: what the numbers show

The provided quarterly profit and loss table (figures in rupees crores) shows sales ranging across multiple quarters, including 49.45 crore (Sep 2023), 52.51 crore (Dec 2023), 52.62 crore (Mar 2024), 32.45 crore (Jun 2024), and 48.75 crore (Mar 2026). Another quarterly table lists net sales of 42.05 crore (Dec 2024), 40.94 crore (Mar 2025), 53.81 crore (Jun 2025), 51.00 crore (Sep 2025), and 42.59 crore (Dec 2025).

For December 2025, the dataset states standalone net sales of ₹42.59 crore, up 1.29% from ₹42.05 crore in December 2024. It also reports quarterly net profit of ₹0.36 crore in December 2025, down 68.74% from ₹1.14 crore in December 2024. EBITDA for December 2025 is reported at ₹3.79 crore, down 5.72% from ₹4.02 crore in December 2024. EPS is reported as having decreased to ₹0.99 in December 2025 from ₹1.42 in December 2024.

Net profit trend: sharp quarter-on-quarter swing, weaker YoY

A separate line in the data states that Everest Organics Ltd’s net profit fell -9.62% since the same period last year to ₹2.63 crore in Q4 2025-2026. The same section also notes a 630.56% jump in net profits on a quarterly growth basis versus the prior three months. Together, these figures indicate that profitability has been volatile, improving sharply sequentially while still showing a decline on a year-on-year comparison.

Investors typically interpret such mixed signals by looking for consistency in operating metrics like sales, operating profit, and interest costs. In the quarterly result table, interest for the periods shown includes ₹1.40 crore (Dec 2024), ₹1.15 crore (Mar 2025), ₹1.31 crore (Jun 2025), ₹1.23 crore (Sep 2025), and ₹1.23 crore (Dec 2025). Operating profit over the same periods is listed as ₹4.02 crore, ₹3.44 crore, ₹4.44 crore, ₹5.13 crore, and ₹3.54 crore, respectively.

Dividend history noted in the dataset

The dataset mentions a dividend declaration in the quarter ending March 2022. Everest Organics declared a dividend of ₹0.50 per share on May 27, 2022, translating to a dividend yield of 0.50%. No newer dividend figures are included in the provided text.

For investors, older dividend history is usually a reference point rather than a signal for future payouts. Any fresh announcement would typically be communicated through board decisions and stock exchange filings, but no such upcoming dividend agenda is stated for the August 14 meeting in the text provided.

Stock price milestones mentioned

The dataset notes that Everest Organics hit an all-time high of ₹536.4 on January 2, 2026. It also provides two more recent price datapoints: EVERESTO at ₹305 as of August 13, 2026, and a BSE reference price of ₹261.75 as of May 8 at 4:00 PM. These points help place the upcoming results event in the context of a stock that has seen large swings over the year.

Price changes around results are often influenced by the gap between expectations and reported numbers, but the dataset does not provide analyst estimates or guidance. As a result, the most concrete near-term catalyst in the text is the board’s approval of unaudited results for the quarter ended June 30, 2026.

Prior board updates referenced: results and leadership changes

The dataset references earlier updates where the board approved unaudited financial results for Q2 and H1 FY2026 ended September 30, 2025, along with a Limited Review Report by statutory auditors. It also mentions the board approved unaudited financial results for Q1 ended June 30, 2025, again accompanied by a Limited Review Report.

Another note says the board approved unaudited financial results for Q3 and nine months ended December 31, 2025, along with the limited review report, with details available on the company website. These references indicate a consistent pattern of publishing unaudited results with auditor review, which provides context for the upcoming August 14 meeting.

Key facts table

What investors may track next

The immediate next datapoint from the company is the unaudited financial results for the quarter ended June 30, 2026. Given the dataset’s mixed profitability indicators, investors typically focus on whether sales recover, whether operating profit sustains, and how interest and other income contribute to the bottom line. The AGM scheduling decision is also part of the board agenda, which can help shareholders plan participation and track governance timelines.

In the absence of management guidance or forecasts in the provided text, the August 14 disclosures are the clearest trigger for new information. Any follow-up communication, including the AGM notice and results documents, would be expected after the board meeting concludes.